SCHEMBL3220166

SCHEMBL3220166

Cc1cc(C(N)=O)cc(C)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
PARP1 P09874 2/20 0.45
ESR1 P03372 2/20 0.44
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2B6 P20813 1/20 0.43
BRD4 O60885 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16281799 0.89 PTPN11 (0.45) CA1CA2PARP1ESR1CYP3A4
SCHEMBL10831613 0.82 PARP1 (0.46) CA1CA2PARP1CYP3A4BRD4
SCHEMBL18471225 0.82 SMN1; SMN2 (0.49) CA1CA2PARP1CYP3A4BRD4
SCHEMBL30924511 0.82 CYP1A2 (0.55) CA1CA2CYP1A2CYP2C9MEN1
SCHEMBL15242142 0.82 CA1 (0.53) CA1CA2PARP1CYP3A4CYP1A2
SCHEMBL1004660 0.80 PARP1 (0.50) CA1CA2PARP1CYP3A4BRD4
SCHEMBL1397262 0.80 POLB (0.50) CA1CA2PARP1CYP3A4CYP1A2
SCHEMBL1448473 0.79 CA1 (0.52) CA1CA2ESR1CYP3A4CYP1A2
SCHEMBL1002938 0.78 CYP3A4 (0.48) PARP1CYP3A4ALDH1A1MAPTSMN1; SMN2
SCHEMBL1003411 0.78 PARP1 (0.43) CA1CA2PARP1CYP3A4BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212286-B2 Methods and systems for coating a surface ALLACCEM, INC. (US) 2015-12-15 US disclosed
EP-1858850-B1 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-01-21 EP disclosed
EP-1858850-B1 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-01-21 EP disclosed
EP-2125026-B1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE ALLACCEM INC (US) 2014-09-24 EP disclosed
WO-2014121036-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX, LLC (US) 2014-08-07 WO disclosed
US-20140221369-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX, LLC (US) 2014-08-07 US disclosed
CN-101175725-B Process for the preparation of opioid modulators JANSSEN PHARMACEUTICA NV 2011-02-02 CN disclosed
US-20100152460-A1 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS CAI CHAOZHONG 2010-06-17 US disclosed
US-20100152460-A1 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS CAI CHAOZHONG 2010-06-17 US disclosed
US-20100152460-A1 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS CAI CHAOZHONG 2010-06-17 US disclosed
EP-1858850-A2 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-28 EP disclosed
WO-2006099060-A2 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-09-21 WO disclosed
WO-2006098982-A1 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-09-21 WO disclosed
US-20060211863-A1 Process for the preparation of opioid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-21 US disclosed
US-20060211861-A1 Process for the preparation of opioid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-21 US disclosed
US-20050227947-A1 Phosphonate analogs for treating metabolic diseases GILEAD SCIENCES, INC. 2005-10-13 US disclosed
WO-2004096237-A2 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES GILEAD SCIENCES, INC. (US) 2004-11-11 WO disclosed
EP-1022272-B1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS SANKYO CO (JP) 2004-05-26 EP disclosed
US-6432993-B1 BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS SANKYO COMPANY, LIMITED (JP) 2002-08-13 US disclosed
EP-1022272-A1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS Sankyo Company Limited (JP) 2000-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221369-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SRD5A2, PPARD, SRD5A1 CA1 2146/4885CA2 1244/4885PARP1 3978/4885
US-20100152460-A1 PROCESS FOR THE PREPARATION OF OPIOID MODULATORS OPRM1, OPRK1, OPRL1 CA1 4252/4885CA2 3697/4885PARP1 4664/4885
US-20060211861-A1 Process for the preparation of opioid modulators OPRM1, OPRK1, OPRL1 CA1 4252/4885CA2 3697/4885PARP1 4664/4885
US-20050227947-A1 Phosphonate analogs for treating metabolic diseases PHOSPHO1, G6PC1, PC CA1 4117/4885CA2 2638/4885PARP1 2197/4885
US-20060211863-A1 Process for the preparation of opioid modulators OPRM1, OPRK1, OPRL1 CA1 4252/4885CA2 3697/4885PARP1 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.